Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 3/20 | 0.43 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 3/20 | 0.41 |
| ▸ | XDH | P47989 | 1/20 | 0.41 |
| ▸ | GPR6 | P46095 | 1/20 | 0.40 |
| ▸ | TBK1 | Q9UHD2 | 3/20 | 0.39 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22470606 | 0.93 | XDH (0.47) | CHRM4EPAS1ARXDHGPR6 | |
| SCHEMBL4426792 | 0.92 | XDH (0.46) | CHRM4EPAS1ARXDHGPR6 | |
| SCHEMBL15819822 | 0.90 | CHRM4 (0.43) | CHRM4EPAS1AR | |
| SCHEMBL22470817 | 0.89 | TBK1 (0.51) | TBK1IKBKE | |
| SCHEMBL3083289 | 0.89 | HTR1A (0.48) | TBK1IKBKE | |
| SCHEMBL29847200 | 0.89 | TBK1 (0.51) | TBK1IKBKE | |
| SCHEMBL29846992 | 0.85 | TBK1 (0.40) | CHRM4EPAS1ARGPR6TBK1 | |
| SCHEMBL23753850 | 0.85 | TBK1 (0.40) | CHRM4EPAS1ARGPR6TBK1 | |
| SCHEMBL22470577 | 0.84 | TBK1 (0.44) | TBK1IKBKE | |
| SCHEMBL29847085 | 0.84 | TBK1 (0.44) | TBK1IKBKE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4105216-B1 | DIHYDRONAPHTHYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | GENFLEET THERAPEUTICS SHANGHAI INC (CN) | 2026-05-20 | — | — | EP | disclosed |
| CN-119823103-A | Polycyclic derivative inhibitor, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2025-04-15 | — | — | CN | disclosed |
| CN-119585261-A | PRMT5 inhibitor, preparation method and application thereof | 上海艾力斯医药科技股份有限公司 | 2025-03-07 | — | — | CN | disclosed |
| CN-115135648-B | Dihydronaphthyridones, preparation method and medical application thereof | 劲方医药科技(上海)有限公司 | 2024-02-09 | — | — | CN | disclosed |
| WO-2024027703-A1 | PRMT5 INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海艾力斯医药科技股份有限公司 | 2024-02-08 | — | — | WO | disclosed |
| US-20230139111-A1 | DIHYDRONAPHTHYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2023-05-04 | — | — | US | disclosed |
| US-20230139111-A1 | DIHYDRONAPHTHYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2023-05-04 | — | — | US | disclosed |
| US-20230139111-A1 | DIHYDRONAPHTHYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2023-05-04 | — | — | US | disclosed |
| US-20230054883-A1 | MTA-Cooperative PRMT5 Inhibitors | Mirati Therapeutics, Inc. | 2023-02-23 | — | — | US | disclosed |
| EP-4105216-A1 | DIHYDRONAPHTHYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2022-12-21 | — | — | EP | disclosed |
| EP-4105216-A1 | DIHYDRONAPHTHYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2022-12-21 | — | — | EP | disclosed |
| US-11479551-B2 | MTA-cooperative PRMT5 inhibitors | Mirati Therapeutics, Inc. (US) | 2022-10-25 | — | — | US | disclosed |
| CN-115135648-A | Dihydronaphthyridinone compounds, preparation method and medical application thereof | 劲方医药科技(上海)有限公司 | 2022-09-30 | — | — | CN | disclosed |
| WO-2021160109-A1 | DIHYDRONAPHTHYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 劲方医药科技(上海)有限公司 | 2021-08-19 | — | — | WO | disclosed |
| WO-2021160109-A1 | DIHYDRONAPHTHYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 劲方医药科技(上海)有限公司 | 2021-08-19 | — | — | WO | disclosed |
| US-20210078994-A1 | MTA-Cooperative PRMT5 Inhibitors | Mirati Therapeutics, Inc. | 2021-03-18 | — | — | US | disclosed |
| US-20210079003-A1 | MTA-Cooperative PRMT5 Inhibitors | Mirati Therapeutics, Inc. | 2021-03-18 | — | — | US | disclosed |
| WO-2021050915-A1 | MTA-COOPERATIVE PRMT5 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2021-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230139111-A1 | DIHYDRONAPHTHYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | RIPK1, RIPK4, RIPK3 | CHRM4 4421/4885EPAS1 451/4885AR 4443/4885 |
| US-11479551-B2 | MTA-cooperative PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | CHRM4 4664/4885EPAS1 1434/4885AR 2726/4885 |
| US-20210079003-A1 | MTA-Cooperative PRMT5 Inhibitors | PRMT5, PRMT1, PRMT3 | CHRM4 4469/4885EPAS1 1565/4885AR 2037/4885 |
| US-20210078994-A1 | MTA-Cooperative PRMT5 Inhibitors | PRMT5, PRMT1, PRMT3 | CHRM4 4469/4885EPAS1 1565/4885AR 2037/4885 |
| US-20230054883-A1 | MTA-Cooperative PRMT5 Inhibitors | PRMT5, PRMT1, PRMT3 | CHRM4 4469/4885EPAS1 1565/4885AR 2037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.